Search
Clinician Ordering Portal
Scientific evidence
Improved prognostic guidance by the 31-gene expression profile test for clinical decisions after a negative lymph node for patients with cutaneous melanoma
Jan 2023
Using 31-GEP results to guide clinical management and surveillance based on personalized risk of MSS can direct care, improving patient outcomes.
Publication: Poster, presented at Winter Clinical Dermatolog conference- Hawaii Jan 13-18 2023
Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomized controlled trials
Jan 2023
Major depressive disorders are prevalent conditions with limited treatment response and remission. Pharmacogenomics tests including CYP2D6 and CYP2C19 genomic variants provide the most reliable actionable approach to guide choice and dosing of antidepressants in major depression to improve outcomes.
Publication: Neuroscience & Behavioral Reviews
Prediction of progression in Barrett’s esophagus using a tissue systems pathology test: a pooled analysis of international multicenter studies
Dec 2022
Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.
Publication: Clinical Gastroenterology and Hepatology
Spatialomics delivered to the clinic for improved health outcomes in Barrett’s esophagus
Dec 2022
The spatialomics approach of TissueCypher brings precision pathology to the clinic for more personalized care of patients with BE to improve outcomes.
Publication: The Journal of Precision Medicine
Prediction of progression in Barrett’s esophagus using a tissue systems pathology test: a pooled analysis of international multicenter studies
Dec 2022
Across all analyses, TissueCypher was the strongest and most significant predictor of progression to HGD or EAC.
Publication: Clinical Gastroenterology and Hepatology
The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms a clinicopathologic-only nomogram at identifying patients who can forego sentinel lymph node biopsy
Nov 2022
Comparison of the i31-GEP for SLNB to the MIA nomogram in patients with T1-T2 tumors with complete data (n=582). The precision of each tool to identify patients with <5% SLN positivity risk was analyzed using 95% confidence intervals.
Publication: SKIN: Journal of Cutaneous Melanoma
The integrated 31-gene expression profile test (i31-GEP) for cutaneous melanoma outperforms the CP-GEP at identifying patients who can forego sentinel lymph node biopsy when applying NCCN guidelines
Nov 2022
Study compared the i31-GEP for SLNB with the CP-GEP to identify patients who can safely forego SLNB.
Publication: SKIN: Journal of Cutaneous Melanoma
A prospective, multi-center clinical utility study demonstrates that the 40-gene expression profile (40-GEP) test impacts clinical management for medicare-eligible patients with high-risk cutaneous squamous cell carcinoma (cSCC)
Nov 2022
The incidence and mortality rates of cutaneous squamous cell carcinoma (cSCC) in the Medicare population are rapidly increasing. The current national guidelines are broad and the available staging systems for stratification are inadequate to accurately guide patient management.
Publication: Skin
Improving patient selection for adjuvant therapy: considerations for the role of the 31-gene expression profile test
Oct 2022
Utilizing patient data provided through collaboration with the NCI SEER program in patients with Stage I-III CM, 31-GEP class result was a significant independent predistor of both MSS and OS. Patients with 31-GEP results in addition to clinicopathologic factors had improved survival.
Publication: Poster, presented at the Society for Melanoma Research Conference, Edinburgh Scotland, October 17-20 2022
Independent validation of TissueCypher to predict progression in community-based Barrett’s esophagus with low grade dysplasia: analysis in a completed prospective study (podium presentation at UEG 2020 annual meeting OP017)
Oct 2022
TissueCypher may be a practical and effective solution to the lack of standardization of expert pathology review of LGD as advocated by all guidelines.
Publication: United European Gastroenterology Journal
An objective spatialomics test standardizes management decisions with potential to improve outcomes for Barrett’s esophagus patients
Oct 2022
This study evaluated the impact that variability in pathologic diagnosis has on patient care and shows how TissueCypher can aid in consistency of BE management.
Publication: Podium presentation (S386) at ACG 2022, Charlotte